San Francisco-based healthcare company Alector announced the closing of a $133 million Series E financing.
The proceeds from the financing will be used to advance Alector’s clinical programs and expand the company’s discovery platform.
Deerfield Management, AbbVie Ventures, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures, New Leaf Venture Partners, Perceptive Advisors, and others participated in the financing.
The financing ensures sufficient resources for the continued development of Alector’s novel drug pipeline.